A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in  multiple myeloma patients who…
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone…
CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission…
CT053, a novel cell-based therapy being developed by Carsgen Therapeutics, was given priority medicines (PRIME) status by the European Medicines Agency (EMA)…
Adding Darzalex (daratumumab) to a combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone — called the VRd combo — increases…
GBR 1342, an investigational bispecific antibody developed by Glenmark Pharmaceuticals, was granted orphan drug designation by the U.S Food and Drug Administration (FDA) for…
Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data…
Designing CAR T-cells to specifically target GPRC5D — a protein appreciably present on the surface of myeloma cells — may be a safe and effective…
Henry Schein, a foundation devoted to promoting dental and medical health, has produced more than 27,000 comfort kits for people fighting cancer in the U.S.
The addition of Keytruda (pembrolizumab) to standard therapy — Revlimid (lenalidomide) or Pomalyst (pomalidomide) in combination with dexamethasone…